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A new ‘silent’ abnormal hemoglobin, Hb Okayama IB2 (NA 2) His + Gln], happened to be discovered 
in a diabetic Japanese female living in Okayama Prefecture, Japan, in the course of glyco-Hb measurement 
of the blood samples of diabetic patients. This variant did not differ from Hb A by conventional 
electrophoretic ests. Only the isoelectric focusing on PAG plate for the determination f glyco-Hb and 
the cation exchanger chromatography were successful in the separation of this abnormal variant from Hb 
A and glyco-Hb. Functional study of the whole blood demonstrated a slight increase of oxygen affinity. 
Hb Okayama 682 (NA 2) His + Gln] Silent Hb variant 
1. INTRODUCTION 
Although most of the abnormal hemoglobins 
discovered to date are different in electrophoretic 
mobility from Hb A, a number of variants are 
almost indistinguishable from Hb A elec- 
trophoretically. These are called ‘silent’ variants, 
and they are detected only by chance when 
hematological abnormality of the carrier’s blood is 
investigated by specialized techniques; e.g., 
oxygen-binding property, isopropanol stability 
test, heat lability test. Otherwise, if these variants 
are normal in function and in physicochemical 
tests, they will escape detection. 
Here, a silent hemoglobin variant, Hb 
Okayama, detected in a diabetic woman through 
the determination of glycosylated hemoglobin 
(glyco-Hb) will be described. 
2. MATERIALS AND METHODS 
Hematological studies were done by conven- 
tional routine procedures. Isoelectric focusing 
(IEF) was performed on Ampholine-PAG plate for 
the determination of glyco-Hb (LKB-Produkter 
AB). Hemoglobin composition of hemolysate was 
examined by elution of the isoelectrofocused in- 
dividual Hb bands and spectrophotometry of the 
eluates. Glyco-Hb component was also analyzed 
by microcolumn chromatographic assay (NC- 
Roppet, Nihon Chemipher) and microcolumn af- 
finity chromatography using glyco . gel B (Pierce 
Chemicals) [l] as well as by IEF. The Hb F content 
was determined by alkali denaturation [2]. The 
erythrocyte 2,3-DPG content was measured by use 
of 2,3-DPG measurement kit (Sigma). Instability 
test was done as in [3]. 
The abnormal hemoglobin fraction was isolated 
from Hb A and purified by large column 
(25 mm x 30 cm) chromatography, on BioRex 70 
(Bio-Rad Chemical Labs.) as in [4] with slight 
modification. After removal of heme from 
purified hemoglobins with HCl-acetone, globins 
were chromatographed on urea-CM-cellulose 
(CM-52, Whatman) as in [5]. A &chain anomaly 
was demonstrated for the abnormal hemoglobin 
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by this chromatography. The abnormal &chain 
(@) was aminoethylated [6], digested with 
TPCK-trypsin (Worthington) and fingerprinted 
on cellulose thin-layer sheet (Chromagram Sheet, 
Eastman-Kodak) [7]. The abnormal peptide was 
eluted, hydrolyzed in constant-boiling HCl and 
analyzed for amino acid composition in an 
automatic amino acid analyzer (Yanaco L-7). 
The oxygen binding properties of a whole blood 
sample (not a hemolysate) studied in phosphate 
buffer solution of pH 7.3 at 37°C by a Hemox- 
Analyzer (TCS, USA) [8]. 
3. RESULTS 
The existence of this abnormal hemoglobin was 
noticed during the process of glyco-Hb examina- 
tion of a 64-year-old woman living in Okayama 
Prefecture who had insulin-dependent diabetes. 
She had been receiving insulin injection repeatedly 
for these 10 years. Hematological studies of her 
peripheral blood were within the normal range 
(RBC 3.97 x 106/& Hb 13.9 g/dl, Ht 38.5%, 
MCV 97 fl, MCH 35.0 pg, Reties 0.9% and Bil(T) 
0.6 mg/dl). The erythrocyte 2,3-DPG content was 
normal: 14.2pmol/g Hb (normal: 11.0-16.2). By 
IEF the abnormal hemoglobin component focused 
anodally from the Hb A band, and overlapped the 
Hb Arc fraction to a certain extent. The band com- 
posed of the abnormal hemoglobin and Hb AI, 
together occupied 47.4% of the total hemoglobin 
of the hemolysate. Other hemoglobin components 
were: Hb AZ (2.6%), Hb A (42.1 To), and abnormal 
glyco-Hb (Hb X,) (7.9Oro), asshown in fig.1. The 
first portion which was eluted early from the col- 
umn of microcolumn chromatographic assay 
(belonging to Hb AI) was 43.1% (normal: 5-7). 
The glyco-Hb level measured simultaneously b  af- 
finity chromatography on glyco . gel B was 13.8% 
(normal: 4.5-6.5). This corresponded to -2-times 
the level of the abnormal glyco-Hb (Hb XI~) frac- 
tion estimated by IEF. Instability test of the whole 
hemolysate was almost negative. 
Oxygen-binding properties of the whole blood 
showed that the &-value was 22.5 mm Hg 
[25-271. This indicates that the abnormal 
hemoglobin has a raised oxygen affinity. 
The fingerprint of the tryptic digest of the 
aminoethylated ,@chain (AE@) revealed absence 
of the m-1 peptide spot at the proper site and 
F&.1. IEF of hemolysates: AZ,Hb AZ; F, Hb F; A, Hb 
A; X, abnormal Hb; AIM, glyco-Hb A; X1,, glyco-Hb X 
(Hb Xc). 
presence of a new abnormal peptide spot which 
was shifted electrophoretically to the anode side 
(fig.2). The amino acid composition of the acid 
hydrolysate of the new peptide indicates that the 
histidine residue at ,&2 is substituted by either 
glutamic acid or glutamine. The abnormal 
hemoglobin is electrophoretically hardly separable 
from Hb A which indicates that they have nearly 
the same electric harge. An amino acid substitu- 
tion His + Gln which causes a slight increase in 
negative charge will be more likely for this abnor- 
mal hemoglobin than that of His + Glu which 
would result in a distinct rise in negative charge. 
Also, the RNA codon for His at m is CAC [9]; this 
can be converted into CAA or CAG which 
specifies Gln by mutational change of one base 
(C + A or G), whereas conversion of His into Glu 
Fig.2. Fingerprint of the tryptic digest of the Aa-,@ 
chain. The dotted circle shows the missing spot of m-1 
peptide. The arrow indicates the spot of the new peptide 
m-1. 
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(GM or GAG) is not possible by the change of 
one base. It is, accordingly, concluded that this 
hemoglobin, which we call Hb Okayama fter the 
name of the Prefecture where the carrier lives, has 
a replacement of ,KZ His by Gln in its abnormal 
chain. Such a variant has not yet been recorded in 
the list of the abnormal hemoglobins in the world 
WI. 
4. DISCUSSION 
The His residues possessing positive electric 
charge at the 2nd position of the fl chains of the 
normal hemoglobin tetramer belong to the 4 pairs 
of cationic groups (Val-1, His-2, Lys-82 and 
His-143 residues of thefl chains) which are directly 
involved in accommodation of organic phosphate 
(such as 2,3-DPG) in the central cavity of the 
hemoglobin molecule [ll]. A 2,3-DPG molecule 
binds to the cluster of the cationic groups lining the 
wall of the central cavity, thus stabilizing the 
deoxy-Hb conformation which has a lowered ox- 
ygen affinity. In Hb Okayama deoxygenation of
its molecule is expected to be incomplete due to 
loss of one of the 2,3-DPG binding sites on ac- 
count of the amino acid substitution of His + Gln 
at the ,& position. This was corroborated by the 
raised oxygen affinity of the whole blood of the 
carrier of Hb Ckayarna (P&silue: 22.5 mm Hg). 
However, the oxygen affinity was not so much in- 
creased as to cause polycythemia ,@I the carrier. 
There is another hemoglobin variant possessing 
an amino acid substitution at the fl site. It is Hb 
Deer Lodge (f32 His + Arg) [12]. Like Hb 
Okayama this variant showed an increased oxygen 
affinity, but no clinical signs [12,13]. 
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